AL·Async + video
Telehealth · MA
Massachusetts
Massachusetts residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — from Boston and Cambridge to the Berkshires and Cape Cod. Pallas Health connects you with a board-certified provider licensed in Massachusetts who can evaluate your eligibility in under 5 minutes and, if appropriate, prescribe medication that ships to any Massachusetts address in a few business days.
- Licensed by
- Massachusetts Board of Registration in Medicine
- Telehealth
- Async + video
- Compounded semaglutide
- Available
- Compounded tirzepatide
- Available
- Medicaid
- Covered with conditions
- Shipping
- 2–3 business days
How telehealth prescribing works in Massachusetts
Massachusetts permits licensed providers to use telehealth to establish a patient relationship and prescribe non-controlled medications like GLP-1s, including synchronous video and, in appropriate cases, asynchronous review.
Massachusetts requires any provider writing a prescription to a Massachusetts resident to hold an active Massachusetts medical license — out-of-state licensure is not sufficient. Under Chapter 260 of the Acts of 2020 (the 2020 telehealth law) and Massachusetts Board of Registration in Medicine telehealth policy, licensed providers may use telemedicine to establish the provider-patient relationship and prescribe non-controlled medications, including via synchronous video and, in appropriate cases, asynchronous review when the standard of care is met. Every Pallas clinician who treats Massachusetts patients is individually licensed by the Massachusetts Board of Registration in Medicine. Importantly, Massachusetts requires telemedicine providers to make provider licensure and identifying information publicly available rather than only during a consultation (Massachusetts Board of Registration in Medicine Policy 15-05 (2015)). Pallas publishes its clinical partners (Lion MD and CareValidate), its named medical leadership, and their NPI numbers — with direct links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical, along with a contact for licensure verification. GLP-1s are not controlled substances, so Massachusetts's separate Prescription Monitoring Program and controlled-substance telemedicine requirements don't add friction here, but our providers still document a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and schedule follow-up visits to monitor response and titrate the dose.
Medicaid & insurance in Massachusetts
Covered with conditions
MassHealth (Massachusetts Medicaid) covers GLP-1s for type 2 diabetes and, with prior authorization and step therapy, for chronic weight management. Compounded GLP-1s are not covered.
Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in Massachusetts
No insurance, and the same price in every Massachusetts ZIP code. You see your full price during intake, before you pay anything.
Compounded plans · provider care included
- Compounded semaglutide$139 first month, then $597 every 12 weeks ($199/mo avg)
- Compounded tirzepatide$179 first month, then $897 every 12 weeks ($299/mo avg)
Your plan price covers your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free and discreet, only if prescribed; refunded in full if a clinician decides treatment isn’t right for you. Cancel anytime. Pay-over-time options are available at checkout.
Brand-name · FDA-approved
FDA-approved Wegovy® and Zepbound® for chronic weight management, plus Ozempic® and Mounjaro® for type 2 diabetes, are available cash-pay from $1,069/mo. Your clinician helps determine which option is appropriate for you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Semaglutide vs tirzepatide in Massachusetts
Both are once-weekly injections available to Massachusetts patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide) produced greater average weight loss than Wegovy® (semaglutide) — roughly 20% versus 14% of body weight over 72 weeks — with broadly similar tolerability. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide plans average $199/mo versus $299/mo for tirzepatide (full terms above), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Massachusetts — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in Massachusetts
We ship to every ZIP code in Massachusetts, including:
- Boston
- Worcester
- Springfield
- Cambridge
- Lowell
- Brockton
- Quincy
- New Bedford
Massachusetts GLP-1 questions
Yes. Massachusetts law allows a licensed Massachusetts provider to establish a patient relationship and prescribe non-controlled medications like semaglutide through telehealth — including asynchronous review of your intake — as long as the standard of care is met. You do not need a prior in-person visit.
MassHealth covers GLP-1s for type 2 diabetes and, with prior authorization and step therapy, for chronic weight management. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service, so MassHealth rules do not affect our pricing.
No. Under Massachusetts Board of Registration in Medicine rules, the prescribing provider must hold an active Massachusetts medical license when treating a patient located in Massachusetts. Every Pallas clinician who treats Massachusetts patients is individually licensed in Massachusetts.
Yes. Under Massachusetts Board of Registration in Medicine Policy 15-05, telemedicine providers must make provider licensure and identifying information publicly available, not only during a consultation. Pallas publishes our clinical partners (Lion MD and CareValidate), our medical leadership, and their NPI numbers — with links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical.
Most Massachusetts patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Boston, Cambridge, Worcester, and the Route 128 corridor typically ship fastest; the Berkshires and Cape Cod may take an extra day.
Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Massachusetts address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.
Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Massachusetts address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.
Yes. FDA-approved Wegovy® and Zepbound® for chronic weight management — plus Ozempic® and Mounjaro® for type 2 diabetes — are available to Massachusetts patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Massachusetts during intake.
That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound® (tirzepatide) produced greater average weight loss than Wegovy® (semaglutide) — about 20% versus 14% of body weight over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Massachusetts weighs your history, goals, and budget to recommend a starting point.
Start your Massachusetts intake